-
Monetary Risk Preferences and Demand for Preventative Treatment: A Discrete Choice Experiment Among Individuals at High Risk for Lung Cancer
10 Feb 2026 22:11 GMT
… the true risk of an event and may differ across individuals … developing lung cancer at the cost of upfront risks of adverse events, or … developing lung cancer at the cost of upfront risks of adverse events, or …
-
Independent Risk Factors and Nomogram-Based Prediction of Pulmonary Fungal Infection in Lung Cancer Inpatients: A Single-Center Retrospective Study
10 Feb 2026 22:10 GMT
… stratification in consecutively hospitalized lung cancer patients, incorporating cellular immune … and the actual observed event rates in both … of immune-related adverse events (irAEs) in cancer … advanced non-small cell lung cancer. Clin Lung Cancer. 2022;23(3 …
-
Use of Inhaled Insulin not associated with increased risk of lung cancer, reports research
10 Feb 2026 13:12 GMT
… showed no increased risk of lung cancer compared with regular human insulin … were the incidence of any lung cancer and a composite outcome … difference in the risk of lung cancer between inhaled insulin and … low in both groups (≤10 events in both groups), with …
-
A pulmonary embolism tied to colorectal cancer killed Catherine O’Hara. Here’s how common the event is among cancer patients
11 Feb 2026 00:55 GMT
… cancer, breast cancer, kidney cancer, lung cancer, melanoma, pancreatic cancer and gynecological … ?
Pulmonary embolisms are common in lung cancer patients, according to researchers in … Anderson notes. However, the second event is “more lethal.”
-
ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in Extensive Stage Small Cell Lung Cancer
09 Feb 2026 13:00 GMT
… Extensive Stage Small-cell Lung Cancer (ES-SCLC) Patients … iadademstat in small cell lung cancer. Combining LSD1 inhibition with … tumors such as small cell lung cancer (SCLC), neuroendocrine tumors ( … of new information, future events, or otherwise. This press …
-
KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
11 Feb 2026 17:30 GMT
… subsequently recovered from the event.
Immune-Mediated Endocrinopathies
… metastatic non–small cell lung cancer (NSCLC), serious adverse … .
Non-Small Cell Lung Cancer
KEYTRUDA and KEYTRUDA QLEX … of new information, future events or otherwise. Additional …
-
Inhalation: A Smart Strategy and Increasing Potential for Drug Delivery
11 Feb 2026 17:18 GMT
… and effective for treating lung tumors with reduced systemic side … 6, and adverse events related to ALIS were … inhaled aerosolized immunotherapeutic for lung cancer: pharmacological profile in mice … et al. Early mucosal events promote distinct mucosal and …
-
<![CDATA[Advancing NSCLC Care: RMAT Status, Treatment Timing, and ASCO Updates]]>
11 Feb 2026 17:10 GMT
… developments in non-small cell lung cancer (NSCLC) highlight the … . Notably, treatment-related adverse events (AEs) were consistent with … or metastatic non-small cell lung cancer. Krystal Biotech, Inc. … in non-small cell lung cancer: a randomized phase 3 …
-
<![CDATA[Repotrectinib Yields Enduring Activity in NTRK+ Solid Tumor Trial]]>
11 Feb 2026 19:02 GMT
… associated with low-grade adverse events, consistent with previous reports,” lead … ROS1-positive non–small cell lung cancer, received repotrectinib at the recommended … , respectively; TRAEs resulted in these events for 3%, 44%, and 42% …
-
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company’s Expanded ADC Pipeline
11 Feb 2026 13:45 GMT
… highly relevant in GI and lung cancers. For more information about the … and uncertainties relating to future events and the future performance of … the Company. Actual events or results may differ materially …
About
© 1995-2026